title: Bone mass and subtle abnormalities in ovulatory function in healthy women.
abstract: Women with occasional anovulatory or short luteal phase menstrual cycles have been reported to lose bone mineral density (BMD) at a greatly accelerated rate compared to women without such abnormalities. To investigate this association, we performed a longitudinal study of BMD in a group of healthy premenopausal women enrolled in a comprehensive study of ovulatory function. Subjects had collected daily urine samples that were analyzed for estrone and progesterone metabolites by enzyme-linked immunoassay. The 53 participants collected urine for an average of 4.1 cycles. Computer algorithms identified 7 (13.2%) women with luteal phase abnormalities (> 1 anovulatory cycle or cycle with luteal phase length < or = 10 days) and 17 (32.1%) women with other menstrual abnormalities. Areal BMD (grams per cm2) was measured at the lumbar spine, hip, and whole body using dual energy x-ray absorptiometry; BMD was measured 2-3 times over an average observation period of 17.5 months. At baseline, women with luteal abnormalities had mean BMD similar to those of the 29 women with no abnormal cycles: lumbar spine, 1.06 vs. 1.09 g/cm2; total hip, 0.95 vs. 0.94 g/cm2; whole body, 1.15 vs. 1.11 g/cm2 (P > 0.10; adjusted for age and weight at baseline, parity, physical activity level, and calcium intake). When compared at follow-up to women with no abnormal cycles, women with luteal abnormalities tended to gain BMD at the spine and hip (P > 0.10). On whole body measurement, women with luteal abnormalities tended to lose BMD compared to women with no abnormal cycles (-1.1%/yr vs. 0%/yr; P = 0.08); however, the magnitude of loss was not unusual for women in this age range and was within the coefficient of variation for replicate measurements. Neither mean luteal phase length, percent time in luteal phase, nor average daily excretion of progesterone metabolites was associated with baseline BMD or percent annual change in BMD at any measurement site. Thus, we did not confirm a relationship between luteal abnormalities and accelerated bone loss in this population of healthy premenopausal women.
authors.affiliation: Reproductive Epidemiology Section, California Department of Health Services, Berkeley, USA.
authors.forename: K
authors.initials: K
authors.lastname: Waller
authors.forename: J
authors.initials: J
authors.lastname: Reim
authors.forename: L
authors.initials: L
authors.lastname: Fenster
authors.forename: S H
authors.initials: SH
authors.lastname: Swan
authors.forename: B
authors.initials: B
authors.lastname: Brumback
authors.forename: G C
authors.initials: GC
authors.lastname: Windham
authors.forename: B
authors.initials: B
authors.lastname: Lasley
authors.forename: B
authors.initials: B
authors.lastname: Ettinger
authors.forename: R
authors.initials: R
authors.lastname: Marcus
mesh_terms: D000293:Adolescent; D000328:Adult; D000465:Algorithms; D000858:Anovulation / Q000503:physiopathology*; D015519:Bone Density; D004797:Enzyme-Linked Immunosorbent Assay; D004970:Estrone / Q000652:urine; D005260:Female; D012739:Gonadal Steroid Hormones / Q000652:urine; D006801:Humans; D008183:Luteal Phase / Q000502:physiology; D008598:Menstruation / Q000502:physiology; D011276:Pregnanediol / Q000031:analogs & derivatives / Q000652:urine
chemical_list: D012739:Gonadal Steroid Hormones; C022270:pregnanediol-3 alpha-glucuronide; D004970:Estrone; D011276:Pregnanediol